NovoCure Ltd (NASDAQ: NVCR) is -32.28% lower on its value in year-to-date trading and has touched a low of $11.70 and a high of $34.13 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NVCR stock was last observed hovering at around $19.26 in the last trading session, with the day’s gains setting it 0.92%.
Currently trading at $20.18, the stock is -2.97% and -18.33% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.93 million and changing 4.78% at the moment leaves the stock -2.94% off its SMA200. NVCR registered 23.80% gain for a year compared to 6-month gain of 20.84%.
The stock witnessed a -16.54% loss in the last 1 month and extending the period to 3 months gives it a -33.86%, and is 5.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.28% over the week and 5.40% over the month.
NovoCure Ltd (NVCR) has around 1488 employees, a market worth around $2.22B and $605.22M in sales. Profit margin for the company is -27.86%. Distance from 52-week low is 72.48% and -40.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.32%).
with sales reaching $147.57M over the same period.The EPS is expected to shrink by -27.01% this year, but quarterly earnings will post 1.40% year-over-year. Quarterly sales are estimated to grow 6.55% in year-over-year returns.
NovoCure Ltd (NVCR) Top Institutional Holders
The shares outstanding are 108.52M, and float is at 98.88M with Short Float at 5.26%.
The top institutional shareholder in the company is FMR LLC with over 16.14 million shares valued at $276.51 million. The investor’s holdings represent 15.0482% of the NVCR Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 12.13 million shares valued at $207.83 million to account for 11.3106 of the shares outstanding. The other top investors are CAPITAL INTERNATIONAL INVESTORS which holds 11.7 million shares representing 10.8601% and valued at over $200.36 million, while VANGUARD GROUP INC holds 10.3736 of the shares totaling 11.13 million with a market value of $190.61 million.
NovoCure Ltd (NVCR) Insider Activity
The most recent transaction is an insider sale by Weinberg Uri, the company’s Chief Innovation Officer. SEC filings show that Weinberg Uri sold 268 shares of the company’s common stock on Mar 03 ’25 at a price of $18.92 per share for a total of $5071.0. Following the sale, the insider now owns 0.17 million shares.
NovoCure Ltd disclosed in a document filed with the SEC on Mar 03 ’25 that Leonard Frank X (EVP, Pres., Novocure Oncology) sold a total of 2,527 shares of the company’s common stock. The trade occurred on Mar 03 ’25 and was made at $18.54 per share for $46841.0. Following the transaction, the insider now directly holds 0.14 million shares of the NVCR stock.
Still, SEC filings show that on Mar 03 ’25, Cordova Ashley (Chief Executive Officer) disposed off 2,053 shares at an average price of $18.54 for $38055.0. The insider now directly holds 204,005 shares of NovoCure Ltd (NVCR).
